Earnings History Data for Voyager Therapeutics, Inc. (VYGR) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
12-11-2024	AH		VYGR	Voyager Therapeutics, Inc.	388.82	-0.16	-0.45	-0.59	Voyager Therapeutics GAAP EPS of -$0.16 beats by $0.29, revenue of $24.63M beats by $12.93M [11/12/2024 4:05 PM]	6.67	-0.16 (-2.34%)	6.77	-0.06 (-0.88%)	5.71 - 11.72	620,020	610,000	5,285
Voyager Therapeutics GAAP EPS of -$0.16 beats by $0.29, revenue of $24.63M beats by $12.93M [11/12/2024 4:05 PM] Voyager Reports Third Quarter 2024 Financial and Operating Results [2024-11-12 04:01PM]
06-08-2024	AH		VYGR	Voyager Therapeutics, Inc.	472.14	-0.18	-0.38	-0.51	Voyager Therapeutics GAAP EPS of -$0.18 beats by $0.23, revenue of $29.58M beats by $20.07M [8/6/2024 5:07 PM]	7.05	-1.13 (-13.86%)	8.50	0.31 (3.79%)	6.06 - 11.72	508,228	360,000	961
Voyager Therapeutics GAAP EPS of -$0.18 beats by $0.23, revenue of $29.58M beats by $20.07M [8/6/2024 5:07 PM]
13-05-2024	AH		VYGR	Voyager Therapeutics, Inc.	458.30	-0.20	-0.44	2.94	Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02M [5/13/2024 4:04 PM]	8.47	-0.01 (-0.12%)	8.84	0.36 (4.25%)	6.06 - 14.34	463,210	470,000	2,479
Voyager Therapeutics up 8% following quarterly beats [5/13/2024 5:41 PM] Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02M [5/13/2024 4:04 PM]
28-02-2024	AH		VYGR	Voyager Therapeutics	360.00	1.25	-0.59	0.00	Voyager Therapeutics GAAP EPS of $1.25 beats by $1.54, revenue of $90.06M beats by $69.42M [2/28/2024 4:04 PM]	8.38	-0.59 (-6.58%)	9.82	0.85 (9.48%)	6.06 - 14.34	1,614,111	510,000	331,261
Voyager Therapeutics GAAP EPS of $1.25 beats by $1.54, revenue of $90.06M beats by $69.42M [2/28/2024 4:04 PM]
06-11-2023	AH		VYGR	Voyager Therapeutics, Inc.	283.16	-0.59	-0.58	0.45	Voyager Therapeutics Non-GAAP EPS of -$0.59 beats by $0.01, revenue of $4.61M beats by $1.7M [11/6/2023 4:22 PM]	6.81	0.32 (4.93%)	6.40	-0.09 (-1.39%)	4.77 - 14.34	316,849	180,000	2,522
Voyager Therapeutics Non-GAAP EPS of -$0.59 beats by $0.01, revenue of $4.61M beats by $1.7M [11/6/2023 4:22 PM]
03-08-2023	PM		VYGR	Voyager Therapeutics, Inc.	400.53	-0.51	-0.59	-0.50	Voyager Therapeutics GAAP EPS of -$0.51 beats by $0.06, revenue of $4.85M beats by $3.25M [8/3/2023 7:09 AM]	9.31	0.31 (3.44%)	9.31	0.0 (0.00%)	4.77 - 14.34	440,135	320,000	1,827
Voyager Therapeutics Q2 2023 Earnings Preview [8/2/2023 4:16 PM] Voyager Therapeutics GAAP EPS of -$0.51 beats by $0.06, revenue of $4.85M beats by $3.25M [8/3/2023 7:09 AM]
09-05-2023	PM	7:00 AM ET (May 9)	VYGR	Voyager Therapeutics, Inc.	348.94	2.94	1.68	-0.56	Voyager Therapeutics GAAP EPS of $2.94 beats by $1.90, revenue of $150.48M beats by $97.98M [5/9/2023 7:10 AM]	10.68	2.37 (28.54%)	8.84	0.53 (6.38%)	4.61 - 11.49	3,290,921	420,000	14,801
Voyager Therapeutics Q1 2023 Earnings Preview [5/8/2023 12:45 PM] Voyager Therapeutics GAAP EPS of $2.94 beats by $1.90, revenue of $150.48M beats by $97.98M [5/9/2023 7:10 AM]
07-03-2023	PM	7:00 AM ET (Mar 7)	VYGR	Voyager Therapeutics, Inc.	273.15	-0.61	-0.57	0.15	Voyager Therapeutics GAAP EPS of -$0.61 misses by $0.06 [3/7/2023 7:05 AM]	7.35	-0.61 (-7.66%)	8.15	0.19 (2.39%)	3.64 - 10.81	640,264	260,000	12,058
Voyager Therapeutics Q4 2022 Earnings Preview [3/6/2023 11:15 AM] Voyager stock pops on getting $25M from Novartis under license deal [3/6/2023 8:13 AM] Voyager Therapeutics GAAP EPS of -$0.61 misses by $0.06 [3/7/2023 7:05 AM]
08-11-2022	PM	6:15 AM ET (Nov 8)	VYGR	Voyager Therapeutics, Inc.	200.19	0.45	-0.19	-0.67	Voyager Therapeutics GAAP EPS of $0.45 beats by $0.79, revenue of $41.1M beats by $32.07M [11/8/2022 7:08 AM]	5.24	0.45 (9.39%)	5.18	0.39 (8.14%)	2.54 - 10.60	214,068	110,000	8,290
Voyager Therapeutics Q3 2022 Earnings Preview [11/7/2022 1:03 PM] Voyager Therapeutics GAAP EPS of $0.45 beats by $0.79, revenue of $41.1M beats by $32.07M [11/8/2022 7:08 AM]
04-08-2022	AH	4:00 PM ET (Aug 4)	VYGR	Voyager Therapeutics, Inc.	239.97	-0.50	-0.56	-0.80	Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02 [8/4/2022 5:14 PM]	6.93	-0.54 (-7.23%)	7.30	-0.17 (-2.28%)	2.46 - 10.60	212,521	130,000	268
Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02 [8/4/2022 5:14 PM] Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results [Aug-04-22 04:01PM] Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models [Aug-03-22 11:30AM]
04-05-2022	AH	After the close (May 4)	VYGR	Voyager Therapeutics	302.00	-0.56	-0.14	0.00	Voyager Therapeutics GAAP EPS of -$0.56, revenue of $0.7M misses by $12.01M [5/4/2022 5:38 PM]	6.85	-1.67 (-19.60%)	8.10	-0.42 (-4.93%)	2.46 - 10.60	739,793	1,030,000	334
Voyager Therapeutics GAAP EPS of -$0.56, revenue of $0.7M misses by $12.01M [5/4/2022 5:38 PM] Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results [May-04-22 04:01PM] Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark [May-04-22 01:22PM] Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting [May-03-22 07:00AM] Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates [May-04-22 05:35PM]
08-03-2022	PM	7:00 AM ET (Mar 8)	VYGR	Voyager Therapeutics	140.00	0.15	-0.36	0.00	Voyager Therapeutics GAAP EPS of $0.15 beats by $0.47, revenue of $28.07M beats by $13.52M [3/8/2022 6:31 AM]	5.61	1.68 (42.75%)	0.0	0.0 (0.00%)	2.46 - 6.08	3,083,322	260,000	0
Voyager Therapeutics GAAP EPS of $0.15 beats by $0.47, revenue of $28.07M beats by $13.52M [3/8/2022 6:31 AM] Voyager stock soars 15% on license deal with Novartis for AAV capsids for gene therapies [3/8/2022 6:12 AM] Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results [Mar-08-22 06:16AM] Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER AAV Capsids for Gene Therapy Programs [Mar-08-22 01:15AM] VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates [Mar-07-22 09:15AM] Voyager, Novartis sign deal worth up to $1.7 billion [Mar-08-22 08:30AM] Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs [Mar-08-22 06:27AM] Voyager inks gene therapy deal with Novartis worth up to $1.8B [Mar-08-22 02:20PM]
02-11-2021	PM	7:00 AM ET (Nov 2)	VYGR	Voyager Therapeutics	137.00	-0.67	-0.75	0.00	Voyager Therapeutics EPS beats by $0.10, misses on revenue [11/2/2021 7:45 AM]	3.89	0.18 (4.85%)	3.89	0.0 (0.00%)	2.46 - 12.00	1,434,283	1,410,000	813
Voyager Therapeutics EPS beats by $0.10, misses on revenue [11/2/2021 7:45 AM] Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results [Nov-02-21 07:00AM] Earnings Preview: Voyager Therapeutics (VYGR) Q3 Earnings Expected to Decline [Nov-01-21 03:02PM] Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue Estimates [Nov-02-21 08:25AM]
10-05-2021	PM		VYGR	Voyager Therapeutics, Inc.	165.00	-0.58	-0.71	0.00	Voyager Therapeutics EPS in-line, misses on revenue [5/10/2021 7:57 AM]	4.11	-0.20 (-4.64%)	4.21	-0.10 (-2.32%)	3.89 - 14.62	698,483	1,240,000	6,037
Voyager Therapeutics EPS in-line, misses on revenue [5/10/2021 7:57 AM] Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates [May-10-21 07:30AM] Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates [May-10-21 08:45AM]
25-02-2021	AH	4:00 PM ET (Feb 25)	VYGR	Voyager Therapeutics, Inc.	242.40	-0.43	-0.52	-0.34	Voyager Therapeutics EPS beats by $0.13, misses on revenue [2/25/2021 4:24 PM]	5.71	-0.52 (-8.35%)	5.90	-0.33 (-5.30%)	5.60 - 14.62	895,111	555,196	36,415
Voyager Therapeutics EPS beats by $0.13, misses on revenue [2/25/2021 4:24 PM] Premarket analyst action - healthcare [2/26/2021 9:27 AM] Benzinga's Top Ratings Upgrades, Downgrades For February 26, 2021 [Feb-26-21 10:04AM] VYGR BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important March 24 Deadline - VYGR [Feb-25-21 10:14PM]
10-08-2020	PM	7:00 AM ET (Aug 10)	VYGR	Voyager Therapeutics, Inc.	408.73	-0.23	-0.75	0.29	Voyager Therapeutics EPS beats by $0.50, beats on revenue [8/10/2020 7:02 AM]	11.50	0.31 (2.74%)	11.50	0.31 (2.77%)	6.26 - 22.13	132,715	250,467	2,341

06-05-2020	PM		VYGR	Voyager Therapeutics, Inc.	393.20	-0.66	-0.89	-0.81	Voyager Therapeutics EPS beats by $0.13, beats on revenue [5/6/2020 7:11 AM]	11.46	0.33 (2.96%)	0.0	0.0 (0.00%)	6.26 - 28.79	266,471	271,509	0